March 26 (Reuters) - Alnylam Pharmaceuticals Inc:
* ALNYLAM RECEIVES EUROPEAN MEDICINES AGENCY PRIME DESIGNATION FOR ACCELERATED ASSESSMENT OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)
* ALNYLAM PHARMACEUTICALS INC - COMPANY INTENDS TO ADVANCE LUMASIRAN TO A PHASE 3 STUDY IN LATE 2018 Source text for Eikon: Further company coverage: